BACKGROUND: Results of previous studies suggest that β-adrenoreceptor activation may augment pain, and that β-adrenoreceptor antagonists may be effective in reducing pain, particularly in individuals not homozygous for the catechol-O-methyltransferase (COMT) high-activity haplotype. MATERIALS AND METHODS:Consenting patients admitted for thermal burn injury at participating burn centers were genotyped; those who were not high-activity COMT homozygotes were randomized to propranolol 240 mg/d or placebo. Primary outcomes were study feasibility (consent rate, protocol completion rate) and pain scores on study days 5 to 19. Secondary outcomes assessed pain and posttraumatic stress disorder symptoms 6 weeks postinjury. RESULTS:Seventy-seven percent (61/79) of eligible patients were consented and genotyped, and 77% (47/61) were genotype eligible and randomized. Ninety-one percent (43/47) tolerated study drug and completed primary outcome assessments. In intention-to-treat and per-protocol analyses, patients randomized to propranolol had worse pain scores on study days 5 to 19. CONCLUSIONS:Genotype-specific pain medication interventions are feasible in hospitalized burn patients. Propranolol is unlikely to be a useful analgesic during the first few weeks after burn injury.
RCT Entities:
BACKGROUND: Results of previous studies suggest that β-adrenoreceptor activation may augment pain, and that β-adrenoreceptor antagonists may be effective in reducing pain, particularly in individuals not homozygous for the catechol-O-methyltransferase (COMT) high-activity haplotype. MATERIALS AND METHODS: Consenting patients admitted for thermal burn injury at participating burn centers were genotyped; those who were not high-activity COMT homozygotes were randomized to propranolol 240 mg/d or placebo. Primary outcomes were study feasibility (consent rate, protocol completion rate) and pain scores on study days 5 to 19. Secondary outcomes assessed pain and posttraumatic stress disorder symptoms 6 weeks postinjury. RESULTS: Seventy-seven percent (61/79) of eligible patients were consented and genotyped, and 77% (47/61) were genotype eligible and randomized. Ninety-one percent (43/47) tolerated study drug and completed primary outcome assessments. In intention-to-treat and per-protocol analyses, patients randomized to propranolol had worse pain scores on study days 5 to 19. CONCLUSIONS: Genotype-specific pain medication interventions are feasible in hospitalized burn patients. Propranolol is unlikely to be a useful analgesic during the first few weeks after burn injury.
Authors: Seth A Eisen; Han K Kang; Frances M Murphy; Melvin S Blanchard; Domenic J Reda; William G Henderson; Rosemary Toomey; Leila W Jackson; Renee Alpern; Becky J Parks; Nancy Klimas; Coleen Hall; Hon S Pak; Joyce Hunter; Joel Karlinsky; Michael J Battistone; Michael J Lyons Journal: Ann Intern Med Date: 2005-06-07 Impact factor: 25.391
Authors: Luda Diatchenko; Gary D Slade; Andrea G Nackley; Konakporn Bhalang; Asgeir Sigurdsson; Inna Belfer; David Goldman; Ke Xu; Svetlana A Shabalina; Dmitry Shagin; Mitchell B Max; Sergei S Makarov; William Maixner Journal: Hum Mol Genet Date: 2004-11-10 Impact factor: 6.150
Authors: Richard Lennertz; Haley Zimmerman; Timothy McCormick; Scott Hetzel; Lee Faucher; Angela Gibson Journal: J Burn Care Res Date: 2020-11-30 Impact factor: 1.845
Authors: Timothy F Platts-Mills; Sean A Flannigan; Andrey V Bortsov; Samantha Smith; Robert M Domeier; Robert A Swor; Phyllis L Hendry; David A Peak; Niels K Rathlev; Jeffrey S Jones; David C Lee; Francis J Keefe; Philip D Sloane; Samuel A McLean Journal: Ann Emerg Med Date: 2015-06-16 Impact factor: 5.721
Authors: Matthew C Mauck; Chloe E Barton; Andrew S Tungate; Jeffrey W Shupp; Rachel Karlnoski; David J Smith; Felicia N Williams; Samuel W Jones; Christopher Sefton; Kyle McGrath; Bruce A Cairns; Samuel A McLean Journal: J Burn Care Res Date: 2022-01-05 Impact factor: 1.845
Authors: Georgina Nakafero; Matthew J Grainge; Ana M Valdes; Nick Townsend; Christian D Mallen; Weiya Zhang; Michael Doherty; Mamas Mamas; Abhishek Abhishek Journal: Rheumatology (Oxford) Date: 2021-12-01 Impact factor: 7.580